The value of pretreatment serum butyrylcholinesterase level as a novel prognostic biomarker in patients with cervical cancer treated with primary (chemo-)radiation therapy.
Nina PoetschAlina SturdzaStefanie AustStephan PolterauerChristoph GrimmSchwameis RichardRichard PötterHeinz KoelblReinthaller AlexanderVeronika SeebacherPublished in: Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] (2019)
Low pretreatment serum BChE levels are associated with advanced tumor stage and poor response to treatment, and serve as an independent prognostic biomarker for shorter PFS, CSS, and OS in patients with cervical cancer treated with primary (chemo-)radiation therapy.